CD33 and acute myeloid leukemia: Finally, Boucher et al. have recently reported the generation of CD123/CD33 bispecific CAR-T cells that seem to have a considerable therapeutic potential and will be evaluated in clinical trials in relapsed/refractory AML patients [121].